Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

BACKGROUND: The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide-1 receptor agonist, versus matched placebo reduced the first outcome of major adverse cardiova...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Diabetol
Autors principals: Dagenais, Gilles R., Rydén, Lars, Leiter, Lawrence A., Lakshmanan, Mark, Dyal, Leanne, Probstfield, Jeffrey L., Atisso, Charles Messan, Shaw, Jonathan E., Conget, Ignacio, Cushman, William C., Lopez-Jaramillo, Patricio, Lanas, Fernando, Munoz, Ernesto German Cordona, Pirags, Valdis, Pogosova, Nana, Basile, Jan, Sheu, Wayne H. H., Temelkova-Kurktschiev, Theodora, Raubenheimer, Peter J., Keltai, Matyas, Hall, Stephanie, Pais, Prem, Colhoun, Helen M., Riddle, Matthew C., Gerstein, Hertzel C.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7690176/
https://ncbi.nlm.nih.gov/pubmed/33239067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01179-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars